| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 305.96 | 229.6% |
| Total Income | 305.96 | 229.6% |
| Expenditure | 459.28 | 34.7% |
| PBT | -162.10 | 36.6% |
| Net Profit | -163.56 | 36.3% |
| OPM | -50.11% | |
| NPM | -53.46% | |
| EPS | -0.76 | 46.5% |
Insmed Reports Q1 2026 Revenue of $306.0 Million
07 May 2026 · 7 May, 4:37 pm
Summary
Insmed Incorporated reported its financial results for the first quarter ended March 31, 2026. Total company revenues for Q1 2026 were $306.0 million. BRINSUPRI revenues grew by 44% compared to the previous quarter, reaching $207.9 million, while ARIKAYCE revenues increased by 6% year-over-year to $98.1 million. The company reiterated its full-year revenue guidance for both BRINSUPRI and ARIKAYCE. Insmed continues to advance its clinical development programs, including the Phase 3 studies for TPIP.
Key Highlights
- 1
Insmed reported total company revenues of $306.0 million for the first quarter of 2026.
- 2
BRINSUPRI revenues reached $207.9 million in Q1 2026, reflecting a 44% growth over Q4 2025.
- 3
ARIKAYCE revenues were $98.1 million for the first quarter of 2026, a 6% increase compared to Q1 2025.
- 4
The company reiterated its 2026 BRINSUPRI revenue guidance of at least $1 billion.
- 5
Insmed also reaffirmed its 2026 ARIKAYCE revenue guidance of $450 million to $470 million.
- 6
The Phase 3b ENCORE study of ARIKAYCE in patients with MAC lung disease met its primary and all multiplicity-controlled secondary culture conversion endpoints.
- 7
The Phase 3 PALM-PAH study of TPIP in patients with PAH was initiated in April 2026.
Management Comments
Will Lewis
“In the first quarter of 2026, momentum across Insmed’s commercial portfolio and pipeline continued to build. The trajectory of the BRINSUPRI launch continues to exceed our expectations, and we are especially encouraged by the positive topline results from the ENCORE Phase 3b study, which could enable us to extend our reach to even more patients. We remain focused on improving bronchiectasis diagnosis, expanding the ARIKAYCE label, advancing our Phase 3 programs for TPIP, and progressing our early-stage pipeline, with the ambition of delivering meaningful innovation and improving the lives of patients with serious diseases.”
Informational and educational content only. Not investment advice.